Juniper Pharma Services to reformulate Pharmaust candidate for Phase II trials
The CDMO will also manufacture 20,000 capsules of the reformulated monepantel solution for the Australian company
Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals has been selected by PharmAust Limited to reformulate monepantel (MPL) for its Phase II studies currently in planning and preparation.
The contract development and manufacturing organisation (CDMO) will also manufacture 20,000 capsules of the reformulated MPL solution for the Australian company under GMP, ensuring that the Phase II clinical data are admissible to regulators as part of any subsequent submissions.
The primary need to reformulate MPL stems from the particularly unpleasant taste of the current MPL formulation, as used at the Royal Adelaide Hospital during the Phase I study. Despite showing significant activity of MPL on tumour markers such as p70S6K and p-4E-BP1, compliance by patients in taking the drug for 28 days was poor due to nausea associated with its exceptionally poor palatability.
Dr Roger Aston, chairman at PharmAust, said: “We expect the reformulation process to take about 12 to 14 weeks, which gives us time to prepare clinical trial submissions to regulatory bodies based on the capsule format.
“We have shown that oral MPL is effectively absorbed in humans and canines yielding blood levels of the drug which have shown both safety and activity against key tumour markers.”
With an established track record of helping pharmaceutical companies develop and produce oral and topical drug products for clinical trials, Juniper Pharma Services is able to optimise formulation performance through its science-led approach to projects.
Dr Nikin Patel, president at Juniper Pharma Services, said: “We are very pleased to have secured this project with PharmAust as it further demonstrates our specific expertise in assisting companies from across the globe in reformulating and manufacturing products such as capsules for clinical trials.
“As our reputation in the market for supporting drug developers with both simple and complex formulation challenges continues to grow, we are seeing more companies approach us at an earlier stage to transform their promising concepts into finished dosage forms to deliver the best possible chance of clinical success.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance